Gabapentin-induced severe myoclonus in a patient with impaired renal function.
Journal of Neurology (Impact Factor: 3.58). 04/2006; 253(3):382-3. DOI: 10.1007/s00415-005-0970-1
Article: Olanzapine-associated myoclonus.[Show abstract] [Hide abstract]
ABSTRACT: Olanzapine is an atypical antipsychotic drug that infrequently has been reported to cause seizures and myoclonus despite a small proconvulsant risk. This is the first report of generalized myoclonus induced in a patient who had been maintained on low dose olanzapine for over seven years without any change in her dose. Olanzapine was discontinued, and the myoclonic jerks completely resolved within 48 h.Epilepsy research 12/2011; 98(2-3):247-50. · 2.48 Impact Factor
Article: Myoclonus.[Show abstract] [Hide abstract]
ABSTRACT: This review examines recent developments in the field of myoclonus. The range of clinical features in myoclonic dystonia has been extended and its underlying pathophysiology better defined. The diverse causes leading to jerky tremor and orthostatic myoclonus have been clarified and the need to consider drugs as potential causes highlighted. In patients with combined myoclonus and epilepsy, the major advance has been in our understanding of the natural history of these conditions, which can be more benign than hitherto thought. Finally, the new condition of primary progressive myoclonus of ageing has been identified, although it remains to be seen whether this is a pathological entity or not. Most progress has been in the characterization of myoclonic syndromes with dystonia and epilepsy. Therapeutic options remain limited, and exploration of the role of functional neurosurgery may be worthwhile in the future, given the debilitating nature of many myoclonic syndromes.Current opinion in neurology 06/2009; 22(4):414-8. · 5.43 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: A 56-year-old man with diabetes, hypertension, and chronic kidney disease presented to the emergency room with a complaint of pain in his right foot. He was found to have tremors. Gabapentin toxicity was suspected and the patient was found to have high gabapentin level (6.3 mcg/ml). Patient was commenced on continuous venovenous hemodiafiltration (CVVHD) and the pharmacokinetics of gabapentin was studied. The patient improved symptomatically and his tremors subsided. In this case report, we describe the successful management of gabapentin toxicity with continuous renal replacement therapy and calculate the clearance of gabapentin which will enable future treatment of gabapentin toxicity by CVVHD.Indian Journal of Nephrology 01/2012; 22(1):59-61.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.